Publications & Research

An Actuarial Analysis Shows That Offering Lung Cancer Screening As An Insurance Benefit Would Save Lives At Relatively Low Cost

Lung cancer screening is not established as a public health practice, yet the results of a recent large randomized controlled trial showed that screening with low-dose spiral computed tomography reduces lung cancer mortality. Using actuarial models, this study estimated the costs and benefits of annual lung cancer screening offered as a commercial insurance benefit in the high-risk US population ages 50–64. Assuming current commercial reimbursement rates for treatment, we found that screening would cost about $1 per insured member per month in 2012 dollars. The cost per life-year saved would be below $19,000, an amount that compares favorably with screening for cervical, breast, and colorectal cancers. Our results suggest that commercial insurers should consider lung cancer screening of high-risk individuals to be high-value coverage and provide it as a benefit to people who are at least fifty years old and have a smoking history of thirty pack-years or more. We also believe that payers and patients should demand screening from high-quality, low-cost providers, thus helping set an example of efficient system innovation.

Click to access the full article.



  • Imaging Forward

    In just 20 years, medical imaging has dramatically improved health outcomes and lowered costs. Imagine what the future holds. Learn More


  • MITA Smart Initiative

    Promoting patient safety and enhancing the quality of medical imaging technology with MITA Smart Standards. Learn More

  • Fluoro Pharma

    Why I Joined MITA – FluoroPharma Medical, Inc.

    Hear from Thomas Tulip, Ph.D, President, FluoroPharma Medical, Inc. on why his organization joined MITA.

    Learn More